Autopsy-proven patient with corticobasal degeneration presenting with visuo-constructive disorders as initial symptoms: How advanced MRI sequences can help clinical practice
Restricted accessResearch articleFirst published online March, 2025
Autopsy-proven patient with corticobasal degeneration presenting with visuo-constructive disorders as initial symptoms: How advanced MRI sequences can help clinical practice
Cortico-basal degeneration (CBD) is a neurodegenerative disease typically responsible for cortico-basal syndrome (CBS) or progressive limb apraxia. Half of CBD patients, however, present atypical symptoms, making the diagnosis difficult.
Objective
We reported the case of a woman in her late sixties (BM208), an unusual case of autopsy-proven CBD, showing early signs of Benson's syndrome or posterior cortical atrophy. In addition, we compared cognitive performance and atrophy in different brain regions of BM208 with other neurodegenerative diseases patients to highlight clinical signs that could have guided the diagnosis earlier.
Methods
We retrospectively compared BM208 to patients with typical amnestic Alzheimer's disease (AD) (n = 18, Mini-Mental State Exam (MMSE) scores between 18 and 24), Benson's syndrome due to AD (n = 3), CBS/progressive supranuclear palsy (PSP) syndrome (n = 5), and Lewy body dementia (LBD) patients (n = 3) and a control group (n = 24). All these participants underwent an MMSE, a complete neuropsychological examination and 3DT1 MRI.
Results
Although BM208 was more severely cognitively impaired overall, her cognitive performance was more similar to Benson's syndrome patients’ cognitive profile compared to CBS patients or any other degenerative pathology (typical AD/LBD). Consistently, although BM208 was more atrophic than all other groups, she showed cortical atrophy that matched a Benson's syndrome pattern more than typical AD or CBS. However, the analysis of subcortical atrophy revealed atrophy of the basal ganglia corresponding CBS cases. Furthermore, visual analyses on sagittal T1 images showed atrophy of the midbrain, characteristic of CBS/PSP syndrome.
Conclusions
These results highlight the additive value of fine-grained MRI subcortical quantification to diagnose non-AD rare neurodegenerative disorders.
KovacsGG. Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol2015; 41: 3–23.
2.
DicksonDWBergeronCChinSS, et al.Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol2002; 61: 935–946.
3.
SaranzaGMWhitwellJLKovacsGG, et al.Corticobasal degeneration. Int Rev Neurobiol2019; 149: 87–136.
4.
BoeveBFLangAELitvanI. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol2003; 54: S15–S19.
5.
DoranMDu PlessisDGEnevoldsonTP, et al.Pathological heterogeneity of clinically diagnosed corticobasal degeneration. J Neurol Sci2003; 216: 127–134.
6.
LitvanIGrimesDALangAE, et al.Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol1999; 246: II1–II5.
ConstantinidesVCParaskevasGPParaskevasPG, et al.Corticobasal degeneration and corticobasal syndrome: a review. Clin Park Relat Disord2019; 1: 66–71.
9.
KouriNWhitwellJLJosephsKA, et al.Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol2011; 7: 263–272.
10.
OideTOharaSYazawaM, et al.Progressive supranuclear palsy with asymmetric tau pathology presenting with unilateral limb dystonia. Acta Neuropathol (Berl)2002; 104: 209–214.
11.
TsuboiYJosephsKABoeveBF, et al.Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord2005; 20: 982–988.
12.
JosephsKA. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain2006; 129: 1385–1398.
13.
KnibbJAXuerebJHPattersonK, et al.Clinical and pathological characterization of progressive aphasia. Ann Neurol2006; 59: 156–165.
14.
JosephsKAPetersenRCKnopmanDS, et al.Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology2006; 66: 41–48.
15.
ArmstrongMJLitvanILangAE, et al.Criteria for the diagnosis of corticobasal degeneration. Neurology2013; 80: 496–503.
16.
GrimesDALangAEBergeronCB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology1999; 53: 1969–1969.
17.
BergeronCDavisALangAE. Corticobasal ganglionic degeneration and progressive supranuclear palsy presenting with cognitive decline. Brain Pathol1998; 8: 355–365.
HofPRVogtBABourasC, et al.Atypical form of Alzheimer’s disease with prominent posterior cortical atrophy: a review of lesion distribution and circuit disconnection in cortical visual pathways. Vision Res1997; 37: 3609–3625.
20.
GaltonCJ. Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain2000; 123: 484–498.
21.
Tang-WaiDFGraff-RadfordNRBoeveBF, et al.Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology2004; 63: 1168–1174.
22.
CrutchSJSchottJMRabinoviciGD, et al.Consensus classification of posterior cortical atrophy. Alzheimers Dement2017; 13: 870–884.
23.
RennerJABurnsJMHouCE, et al.Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology2004; 63: 1175–1180.
24.
ChapleauMLa JoieRYongK, et al.Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis. Lancet Neurol2024; 23: 168–177.
25.
RouleauISalmonDPButtersN, et al.Quantitative and qualitative analyses of clock drawings in Alzheimer’s and Huntington’s disease. Brain Cogn1992; 18: 70–87.
26.
MorrisJCHeymanAMohsRC, et al.The consortium to establish a registry for Alzheimer’s disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology1989; 39: 1159–1159.
27.
ReitanRM. The relation of the trail making test to organic brain damage. J Consult Psychol1955; 19: 393–394.
28.
DuboisBVillainNFrisoniGB, et al.Clinical diagnosis of Alzheimer’s disease: recommendations of the international working group. Lancet Neurol2021; 20: 484–496.
29.
ScheltensPLaunerLJBarkhofF, et al.Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol1995; 242: 557–560.
30.
FazekasFChawlukJAlaviA, et al.MR Signal abnormalities at 1.5T in Alzheimer’s dementia and normal aging. Am J Roentgenol1987; 149: 351–356.
31.
HanseeuwBJMalotauxVDricotL, et al.Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study. Eur J Nucl Med Mol Imaging2021; 48: 302–310.
32.
IvanoiuADricotLGilisN, et al.Classification of non-demented patients attending a memory clinic using the new diagnostic criteria for Alzheimer’s disease with disease-related biomarkers. J Alzheimers Dis2014; 43: 835–847.
33.
HauserRAMurtaughFRAkhterK, et al.Magnetic resonance imaging of corticobasal degeneration. J Neuroimaging1996; 6: 222–226.
34.
KatoNAraiKHattoriT. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci2003; 210: 57–60.
35.
ThalDRRübUOrantesM, et al.Phases of aβ-deposition in the human brain and its relevance for the development of AD. Neurology2002; 58: 1791–1800.
36.
MirraSSHeymanAMcKeelD, et al.The consortium to establish a registry for Alzheimer’s disease (CERAD): part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology1991; 41: 479–479.
37.
BennettDASchneiderJAArvanitakisZ, et al.Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology2006; 66: 1837–1844.
MalotauxVColmantLQuenonL, et al.Suspecting non-Alzheimer’s pathologies and mixed pathologies: a comparative study between brain metabolism and tau images. J Alzheimers Dis2024; 97: 421–433.
41.
GérardTColmantLMalotauxV, et al.The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease. Eur J Nucl Med Mol Imaging2024; 51: 1662–1674.
42.
McKeithIGBoeveBFDicksonDW, et al.Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology2017; 89: 88–100.
43.
HöglingerGURespondekGStamelouM, et al.Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria: MDS clinical diagnostic criteria for PSP. Mov Disord2017; 32: 853–864.
44.
Van Der LinderMCoyetteFPoitrenaudJ, et al. L'épreuve de rappel libre / rappel indicé à 16 items (RL/RI-16). Marseille: Solal, 2004.
45.
De PartzM-PBilocqVDe WildeV. Lexis: tests pour le diagnostic des troubles lexicaux chez le patient aphasique. Louvain-la-Neuve [Belgique]: De Boeck Solal, 2012.
46.
BianconiCBusignyT. Les Séries Graphiques : carnet d’utilisation. [Unpublished], 2005.
47.
Van LaethemA. Le « Test des Séries Graphiques » : évaluation méthodologique et normalisation d’un test évaluant les fonctions exécutive. [Mémoire en licence psychologiques non publié], 2006.
48.
DuboisBTouchonJPortetF, et al.Les 5 mots”, épreuve simple et sensible pour le diagnostic de la maladie d’Alzheimer. La Presse Médicale2002; 31: 1696–1699.
49.
FischlB. Freesurfer. NeuroImage2012; 62: 774–781.
50.
DesikanRSSégonneFFischlB, et al.An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage2006; 31: 968–980.
51.
DestrieuxCFischlBDaleA, et al.Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature. Neuroimage2010; 53: 1–15.
52.
CroisileBAstierJ-LBeaumontC, et al.Le Test des cinq mots dans les formes légères de maladie d’Alzheimer : comparaison du score total, du Score Total Pondéré, du Score d’apprentissage et du Score de mémoire dans trois classes d’âge (60 ans, 70 ans, 80 ans). Rev Neurol (Paris)2010; 166: 711–720.
53.
SakaeNJosephsKALitvanI, et al.Clinicopathologic subtype of Alzheimer’s disease presenting as corticobasal syndrome. Alzheimers Dement2019; 15: 1218–1228.
54.
BaiardiSCapellariSLadoganaA, et al.Revisiting the Heidenhain variant of Creutzfeldt-Jakob disease: evidence for prion type variability influencing clinical course and laboratory findings. J Alzheimers Dis2016; 50: 465–476.
55.
KogaSJosephsKAAibaI, et al.Neuropathology and emerging biomarkers in corticobasal syndrome. J Neurol Neurosurg Psychiatry2022; 93: 919–929.
56.
MontineTJPhelpsCHBeachTG, et al.National institute on aging–Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol (Berl)2012; 123: 1–11.
57.
HymanBTPhelpsCHBeachTG, et al.National institute on aging–Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement2012; 8: 1–13.
58.
JellingerKAGrazerAPetrovicK, et al.Four-repeat tauopathy clinically presenting as posterior cortical atrophy: atypical corticobasal degeneration?Acta Neuropathol (Berl)2011; 121: 267–277.
59.
PengGLiuPHeF, et al.Posterior cortical atrophy as a primary clinical phenotype of corticobasal syndrome with a progranulin gene rs5848 TT genotype. Orphanet J Rare Dis2016; 11: 13.
60.
SpagnoloFCeppiDCardamoneR, et al.Frontotemporal dementia with parkinsonism presenting as posterior cortical atrophy. Mov Disord2011; 26: 2131–2132.
61.
ConstantinidesVCParaskevasGPEfthymiopoulouE, et al.Clinical, neuropsychological and imaging characteristics of Alzheimer’s disease patients presenting as corticobasal syndrome. J Neurol Sci2019; 398: 142–147.
62.
LeiguardaRLeesAJMerelloM, et al.The nature of apraxia in corticobasal degeneration. J Neurol Neurosurg Psychiatry1994; 57: 455–459.
63.
JacobsDHAdairJCMacauleyB, et al.Apraxia in corticobasal degeneration. Brain Cogn1999; 40: 336–354.
64.
ForoutanPMurrayMEFujiokaS, et al.Progressive supranuclear palsy: high-field-strength MR microscopy in the human substantia nigra and globus pallidus. Radiology2013; 266: 280–288.
65.
ArabiaGMorelliMPaglionicoS, et al.An magnetic resonance imaging T2*-weighted sequence at short echo time to detect putaminal hypointensity in Parkinsonisms. Mov Disord2010; 25: 2728–2734.
66.
BakshiRBenedictRHBBermelRA, et al.T2 hypointensity in the deep gray matter of patients with multiple sclerosis: A quantitative magnetic resonance imaging study. Arch Neurol2002; 59: 62.
67.
YekhlefFBallanGMaciaF, et al.Routine MRI for the differential diagnosis of Parkinson’s disease, MSA, PSP, and CBD. J Neural Transm2003; 110: 151–169.
68.
KruerMCBoddaertNSchneiderSA, et al.Neuroimaging features of neurodegeneration with brain iron accumulation. Am J Neuroradiol2012; 33: 407–414.
69.
RaoSSAdlardPA. Untangling tau and iron: exploring the interaction between iron and tau in neurodegeneration. Front Mol Neurosci2018; 11: 276.
70.
SteeleJC. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol1964; 10: 333.
71.
WhitwellJL. Clinical and neuroimaging features of the progressive supranuclear palsy- corticobasal degeneration continuum. Curr Opin Neurol2023; 36: 283–290.
72.
RobinsonJLYanNCaswellC, et al.Primary tau pathology, not copathology, correlates with clinical symptoms in PSP and CBD. J Neuropathol Exp Neurol2020; 79: 296–304.
73.
HöglingerGUKassubekJCsotiI, et al.Differentiation of atypical Parkinson syndromes. J Neural Transm2017; 124: 997–1004.
74.
ShirDPhamNTTBothaH, et al.Clinicoradiologic and neuropathologic evaluation of corticobasal syndrome. Neurology2023; 101: e289–e299.
75.
ConstantinidesVCTentolouris-PiperasVParaskevasGP, et al.Hippocampal subfield volumetry in corticobasal syndrome of diverse underlying pathologies. J Neurol2023; 270: 2059–2068.
76.
ArmstrongRACairnsNJ. Comparative quantitative study of ‘signature’ pathological lesions in the hippocampus and adjacent gyri of 12 neurodegenerative disorders. J Neural Transm2015; 122: 1355–1367.
77.
NestorPJFryerTDHodgesJR. Declarative memory impairments in Alzheimer’s disease and semantic dementia. Neuroimage2006; 30: 1010–1020.
78.
La JoieRPerrotinADe La SayetteV, et al.Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer’s disease and semantic dementia. Neuroimage Clin2013; 3: 155–162.
